Get the Stockscreener App
8.28
4.81%
0.38
Pre-market:
8.43
0.15
+1.81%
Gyre Therapeutics Inc stock is traded at $8.28, with a volume of 100.43K.
It is up +4.81% in the last 24 hours and up +6.56% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$7.90
Open:
$8.07
24h Volume:
100.43K
Relative Volume:
1.25
Market Cap:
$797.64M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
88.56
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
-4.28%
1M Performance:
+6.56%
6M Performance:
+9.23%
1Y Performance:
-24.04%
1-Day Range:
$8.02
$8.48
1-Week Range:
$7.83
$8.98
52-Week Range:
$6.11
$13.75
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(858) 567-7770
Address
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
8.28 | 761.03M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | Jefferies | Buy |
| Aug-26-25 | Initiated | H.C. Wainwright | Buy |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
GYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction - Yahoo Finance
GNI Group’s Gyre Therapeutics to acquire Cullgen in $300 million all-stock deal - TipRanks
Gyre, Cullgen Merge In $300M All-Stock Deal - Law360
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 8.2%Should You Buy? - MarketBeat
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead - Stocktwits
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock By Investing.com - Investing.com UK
H.C. Wainwright reiterates Buy on Gyre Therapeutics stock - Investing.com Nigeria
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger - TipRanks
Gyre Therapeutics (NASDAQ: GYRE) inks $300M all-stock Cullgen deal - Stock Titan
Gyre Therapeutics enters into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline - marketscreener.com
Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline - TradingView
Gyre Therapeutics to acquire Cullgen for $300 million - Investing.com
Gyre Therapeutics Enters into Agreement to Acquire Cullgen - GlobeNewswire
getLinesFromResByArray error: size == 0 - mfd.ru
Gyre Therapeutics, Inc. entered into an agreement to acquire Cullgen Inc. - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 111% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Risks Report: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Big Picture: How do insiders feel about Gyre Therapeutics Inc2025 Valuation Update & Trade Opportunity Analysis - baoquankhu1.vn
GYREGyre Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aug Selloffs: Can Gyre Therapeutics Inc expand into new marketsJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Recommendation of “Hold” by Brokerages - Defense World
Can Gyre Therapeutics Inc. scale operations efficientlyJuly 2025 Weekly Recap & Daily Entry Point Trade Alerts - mfd.ru
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Capitalizing on a Promising 113.78% Upside - DirectorsTalk Interviews
Market Catalysts: Can Gyre Therapeutics Inc weather a recessionTreasury Yields & Daily Entry Point Trade Alerts - baoquankhu1.vn
Can Gyre Therapeutics Inc. maintain its current growth ratePortfolio Update Report & Safe Entry Zone Tips - mfd.ru
GNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty - TipRanks
High Growth Tech Stocks in US for February 2026 - simplywall.st
Will Gyre Therapeutics Inc outperform tech stocks2025 Price Action Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) Last Week's 8.5% Decline Must Have Disappointed Public Companies Who Have a Significant Stake - 富途牛牛
Returns Recap: Is TENPREs ROIC above industry averageWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a Promising 139.68% Upside Potential - DirectorsTalk Interviews
Gyre Therapeutics slumps 16%, prices $20M stock offering - MSN
What dividend growth rate does Gyre Therapeutics Inc. offer2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - mfd.ru
Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX) - Defense World
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Eyeing a 119% Upside with a Strong Buy Consensus - DirectorsTalk Interviews
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 2.4%Still a Buy? - MarketBeat
Big Money Moves: Is MicroSectors Travel 3X Leveraged ETNs due May 29 2042 showing insider buyingWeekly Trading Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Aug Big Picture: Is Gyre Therapeutics Inc a turnaround storyJuly 2025 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Trade Recap: Can Palantir Technologies Inc navigate macro headwindsMarket Risk Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: A Potential 123% Upside in the Biotech Space - DirectorsTalk Interviews
US Stocks Recap: Can Gyre Therapeutics Inc expand into new marketsWeekly Trade Analysis & Community Driven Trade Alerts - baoquankhu1.vn
Portfolio Recap: Is BCGWW a good ESG investment2025 Market Overview & Community Verified Swing Trade Signals - baoquankhu1.vn
Quarterly Risk: Does Evolus Inc have high return on assetsJuly 2025 WrapUp & High Accuracy Swing Trade Signals - baoquankhu1.vn
Tech Rally: Is TRTNPRC stock a value trapWeekly Risk Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Pulse: Will Gyre Therapeutics Inc outperform tech stocksJuly 2025 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
Ideas Watch: What are analysts price targets for Gyre Therapeutics IncIPO Watch & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):